New One-Shot Gene Editing Therapy May Reduce Bad Cholesterol By 62%

New One-Shot Gene Editing Therapy May Reduce Bad Cholesterol By 62%

A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62% after a single infusion in an early trial, raising hopes for a long-lasting treatment to reduce heart attack risk

Could Gene Therapy Become The ‘Ozempic’ For Bad Cholesterol? 6 Things To Know About Eli Lilly’s Breakthrough Research

Eli Lilly and Verve Therapeutics’ experimental gene-editing therapy VERVE-102 is showing promising results in lowering bad cholesterol with a single dose.

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced dose-dependent reductions in circulating PCSK9 protein and LDL cholesterol in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

1-time gene therapy can cut bad cholesterol by up to 62%: Study

India News: NEW DELHI: In a major medical breakthrough, scientists have shown that a one-time gene therapy can sharply lower \"bad\" cholesterol for at least a year.

‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose

Pharma giant Eli Lilly announced Monday that its experimental gene-editing therapy can reduce LDL ("bad") cholesterol by up to 62% with a single infusion.

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

(MedPage Today) -- An investigational gene therapy passed muster for reducing PCSK9 and LDL cholesterol levels, with reassuring safety, among patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease ...